SCHEMBL29133716

SCHEMBL29133716

CCC1(Nc2ncnc3ccc(-c4cnc(C)c(N)c4)cc23)C=CC=CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 15/20 0.39
▸ USP2 O75604 2/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ CYP2D6 P10635 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ CLK4 Q9HAZ1 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ EGFR P00533 1/20 0.36
▸ MAP4K4 O95819 1/20 0.35
▸ CLK1 P49759 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29133728 0.89 IRAK4 (0.48) IRAK4USP2CYP1A2CYP3A4CYP2D6
SCHEMBL29133774 0.86 IRAK4 (0.47) IRAK4CYP1A2CYP3A4HSD17B10CLK4
SCHEMBL29133748 0.84 EGFR (0.47) USP2CYP1A2CYP3A4CYP2D6CLK4
SCHEMBL29133764 0.84 PIK3CA (0.37) IRAK4USP2CYP1A2CYP3A4CYP2D6
SCHEMBL29133742 0.83 IRAK4 (0.35) IRAK4USP2CYP1A2CYP3A4CYP2D6
SCHEMBL29133732 0.82 PIK3CA (0.52) IRAK4USP2CYP1A2CYP3A4CYP2D6
SCHEMBL29133743 0.81 PIK3CA (0.53) USP2CYP1A2CYP3A4CYP2D6HSD17B10
SCHEMBL29133739 0.79 HTT (0.50) IRAK4CYP1A2CYP3A4CYP2D6ALDH1A1
SCHEMBL29133745 0.79 HTT (0.50) IRAK4CYP1A2CYP3A4CYP2D6ALDH1A1
SCHEMBL29133735 0.78 HTT (0.36) IRAK4CLK4EGFRMAP4K4CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117295716-A Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors 麦克尼斯迪克治疗有限公司 2023-12-26 — — CN disclosed
Send feedback